Compare ARK Genomic Revolution ETF (ARKG) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Morgan Stanley — how do they compare? ARK Genomic Revolution ETF trades at $40.88, while Morgan Stanley trades at $219 (market cap $350.60B). The key difference: Morgan Stanley pays a 1.8% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | MS | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $227.19 |
52-Week Low | $23.09 | $139.09 |
Market Cap | — | $350.60B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Morgan Stanley (MS) trades at $222.28, up 0.07% on the day, with a bullish technical outlook and strong fundamental performance. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $3.43 surpassing the $3.02 estimate. Revenue growth accelerated to $66.0B in 2025, driving net income to $16.9B. The stock benefits from positive analyst sentiment, including involvement in high-profile deals like the Anthropic IPO.
The outlook remains positive given earnings momentum and a consensus price target of $225.80, though risks include volatile cash flows and rising debt levels. Investor sentiment is bolstered by strategic initiatives like AI integration in wealth management, but macroeconomic sensitivity and competitive pressures warrant monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
